Latest Industry Insights

Botulinum neurotoxins are widely used in both therapeutic and cosmetic applications, but Ipsen says that their new rBoNT-E toxin is a step up from compounds based on the much more widely used serotype A toxin. We spoke to Ipsen Senior Vice President Neurosciences R&D, Philippe Picaut, to find out more.

A recently announced collaboration between Juvenescence, Ltd., and NetraMark Corp. has yielded a new joint venture, NetraPharma, which aims to fight aging-related conditions. We spoke with NetraMark founder Dr. Joseph Geraci to find out more about how the process of targeting and treating neurodegenerative disorders will be radically changed by AI.

Accurate protein characterization is particularly important in the biopharmaceutical industry, where product modifications can affect efficacy and safety. Here, we speak to Matthew Lauber, a consulting scientist who elaborates on the importance and challenges of biotherapeutic protein characterization, and discusses different techniques used for charge variant analysis.

In this blog, Fan Fan, Vice President of Product Management at DNAnexus, a company focused on biomedical informatics and data management, discusses trends in translational informatics and how it has begun to revolutionize healthcare.

Ensuring that data is reliable, reproducible, and therefore valuable means companies in both regulated and non-regulated spaces must keep data integrity at the heart of their informatics operations. We talked to John Zenk, Validation Services Manager at laboratory informatics consultancy CSols, Inc, to find out what the biggest concerns in data integrity are and how companies can take steps to overcome these challenges.

Clinical treatments for neurological and mood disorders like social anxiety disorder and major depressive disorder have failed to show consistent efficacy in treating patients. VistaGen Therapeutics is aiming to correct that. We talked to VistaGen’s CEO, Shawn Singh, about the need for treatments in this area and why Vistagen thinks their compounds AV-101 and PH94B could be promising therapies.

This blog highlights the key advantages and drawbacks of hybridoma development and phage display for a monoclonal antibody production in order to help you determine the best method for your needs.

Many biological processes, specifically the immune system, operate at a cellular level. CytoReason have harnessed this knowledge to build computational, high-resolution, mechanistic models for a range of diseases that enables better discovery and validation of drug targets.

We caught up with Abcam's Head of Custom Services, Jamie Campbell, who recently presented at the Protein & Antibody Engineering Summit, Europe. Jamie discusses the company’s approach to discovering antibodies – key reagents in drug discovery, in vitro diagnostics and therapeutics.

We spoke to Dr Jack Regan, CEO of LexaGene, a biotechnology company developing a fully automated pathogen detection platform, and inventor of their patented microfluidic system, about the foundations and evolution of the system, and the future outlook for the tool.